Trademark: 88830833
Word
TRIVAIR
Status
Pending
Status Code
653
Status Date
Wednesday, February 7, 2024
Serial Number
88830833
Mark Type
4000
Filing Date
Wednesday, March 11, 2020

Trademark Owner History

Classifications
5 Inhalers filled with pharmaceutical preparations for use in the treatment of respiratory diseases, disorders and infections; inhalers filled with pharmaceutical preparations for use in the treatment of asthma; inhalers filled with pharmaceutical preparations for use in the treatment of chronic obstructive pulmonary disease; inhalers filled with pharmaceutical preparations for use in the treatment of rhinitis; inhalers filled with pharmaceutical preparations for use in the treatment of sinus polyps; inhalers filled with pharmaceutical preparations for use in the treatment of viral airway infections; inhalers filled with pharmaceutical preparations for use in the treatment of multiple sclerosis; inhalers filled with pharmaceutical preparations for use in the treatment of depression; inhalers filled with pharmaceutical preparations for use in the treatment of epilepsy; inhalers filled with pharmaceutical preparations for use in the treatment of migraine; inhalers filled with pharmaceutical preparations for use in the treatment of Alzheimer's disease; inhalers filled with pharmaceutical preparations for use in the treatment of Parkinson's disease; inhalers filled with pharmaceutical preparations for use in the treatment of cerebrovascular accident or stroke; inhalers filled with pharmaceutical preparations for use in the treatment of traumatic brain injury; inhalers filled with pharmaceutical preparations for use in the treatment of cancer; inhalers filled with pharmaceutical preparations for use in the treatment of nausea; inhalers filled with pharmaceutical preparations for use in the treatment of post-traumatic stress disorder; inhalers filled with pharmaceutical preparations for use in the treatment of amyotrophic lateral sclerosis; inhalers filled with pharmaceutical preparations for use in the treatment of chronic pain; inhalers filled with pharmaceutical preparations for use in the treatment of insomnia; inhalers filled with pharmaceutical preparations for use in the relief of pain; inhalers filled with pharmaceutical preparations for use in the treatment of cough or sore throat; inhalers filled with pharmaceutical preparations for use in the treatment of candida infection; inhalers filled with pharmaceutical preparations for use in anti-fungal treatment; inhalers filled with pharmaceutical preparations for use in sedation; inhalers filled with pharmaceutical preparations for use in hormone replacement therapy; inhalers filled with pharmaceutical preparations for use in the treatment of psychosis; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of respiratory diseases, disorders and infections; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of asthma; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of chronic obstructive pulmonary disease; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of rhinitis; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of sinus polyps; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of viral airway infections; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of multiple sclerosis; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of depression; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of epilepsy; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of migraine; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of Alzheimer's disease; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of Parkinson's disease; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of cerebrovascular accident or stroke; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of traumatic brain injury; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of cancer; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of nausea; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of post-traumatic stress disorder; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of amyotrophic lateral sclerosis; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of chronic pain; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of insomnia; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the relief of pain; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of cough or sore throat; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of candida infection; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in anti-fungal treatment; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in sedation; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in hormone replacement therapy; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of psychosis; inhalers used to deliver therapeutic agents, namely, analgesics, sedatives, vaccines, anesthetics, insulin, antiemetics, antifungals, hormones, or antipsychotics; drug delivery devices, namely, breath actuated nasal delivery devices used to deliver therapeutic agents, namely, analgesics, sedatives, vaccines, anesthetics, insulin, antiemetics, antifungals, hormones, or antipsychotics; inhalers filled with analgesics, sedatives, vaccines, anesthetics, insulin, antiemetics, antifungals, hormones, respiratory therapeutic agents, or antipsychotics; drug delivery devices, namely, breath actuated nasal delivery devices filled with analgesics, sedatives, vaccines, anesthetics, insulin, antiemetics, antifungals, hormones, respiratory therapeutic agents, or antipsychotics; none of the foregoing containing cannabis or CBD
10 Medical apparatus and instruments, namely, inhalers, sold empty, for therapeutic use; medical apparatus and instruments, namely, breath actuated nasal drug delivery devices, sold empty, for therapeutic use; none of the foregoing for use with cannabis or CBD

Trademark Events
Feb 7, 2024
Notification Of Letter Of Suspension E-Mailed
Feb 7, 2024
Letter Of Suspension E-Mailed
Feb 7, 2024
Suspension Letter Written
Feb 2, 2024
Assigned To Examiner
Jan 30, 2024
Teas/Email Correspondence Entered
Jan 30, 2024
Correspondence Received In Law Office
Jan 30, 2024
Assigned To Lie
May 15, 2023
Teas Response To Suspension Inquiry Received
Nov 15, 2022
Notification Of Inquiry As To Suspension E-Mailed
Nov 15, 2022
Inquiry To Suspension E-Mailed
Nov 15, 2022
Suspension Inquiry Written
Oct 28, 2022
Teas Change Of Correspondence Received
Oct 28, 2022
Teas Change Of Domestic Representatives Address
Oct 28, 2022
Attorney/Dom.Rep.Revoked And/Or Appointed
Oct 28, 2022
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
May 18, 2022
Notification Of Letter Of Suspension E-Mailed
May 18, 2022
Letter Of Suspension E-Mailed
May 18, 2022
Suspension Letter Written
May 18, 2022
Teas/Email Correspondence Entered
May 18, 2022
Correspondence Received In Law Office
May 11, 2022
Assigned To Lie
May 10, 2022
Notice Of Revival - E-Mailed
May 9, 2022
Teas Response To Office Action Received
May 9, 2022
Petition To Revive-Granted
May 9, 2022
Teas Petition To Revive Received
May 3, 2022
Abandonment Notice E-Mailed - Failure To Respond
May 3, 2022
Abandonment Notice Mailed - Failure To Respond
May 3, 2022
Abandonment - Failure To Respond Or Late Response
May 3, 2022
Assigned To Examiner
Oct 5, 2021
Notification Of Inquiry As To Suspension E-Mailed
Oct 5, 2021
Inquiry To Suspension E-Mailed
Oct 5, 2021
Suspension Inquiry Written
Sep 1, 2021
Suspension Checked - To Attorney For Action
Jan 8, 2021
Notification Of Letter Of Suspension E-Mailed
Jan 8, 2021
Letter Of Suspension E-Mailed
Jan 8, 2021
Suspension Letter Written
Jan 5, 2021
Examiner's Amendment Entered
Jan 5, 2021
Notification Of Examiners Amendment E-Mailed
Jan 5, 2021
Examiners Amendment E-Mailed
Jan 5, 2021
Examiners Amendment -Written
Sep 14, 2020
Notification Of Non-Final Action E-Mailed
Sep 14, 2020
Non-Final Action E-Mailed
Sep 14, 2020
Non-Final Action Written
Sep 14, 2020
Assigned To Examiner
Jun 17, 2020
Assigned To Examiner
Jun 2, 2020
Assigned To Examiner
Mar 18, 2020
New Application Office Supplied Data Entered
Mar 14, 2020
New Application Entered

Trademark Alertz updated from USPTO on 2030-01-24